Plasma P ‐selectin is an early marker of thromboembolism in COVID ‐19

  1. Bánk G. Fenyves
  2. Arnav Mehta
  3. MGH COVID‐19 Collection & Processing Team
  4. Kyle R. Kays
  5. Caroline Beakes
  6. Justin Margolin
  7. Marcia B. Goldberg
  8. Nir Hacohen
  9. Michael R. Filbin

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1002/ajh.26372
  2. ScreenIT

    SciScore for 10.1101/2021.07.10.21260293: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The institutional review board waived informed consent.
    Consent: The institutional review board waived informed consent.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    Analysis: All statistical analysis was done in RStudio (version 4.0.3).
    RStudio
    suggested: (RStudio, RRID:SCR_000432)
    Plots were generated using standard functions and the ggplot2 package in R.
    ggplot2
    suggested: (ggplot2, RRID:SCR_014601)

    Results from OddPub: Thank you for sharing your code and data.

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study has limitations. First, the single-center observational study design necessitates external validation. Second, a causal link between endothelial activation, P-selectin levels, and VTE cannot be made. Third, serial sampling was only done in those still hospitalized, which biases later samples toward sicker patients. Fourth, the biomarkers were limited to those available on the two proteomic platforms. Fifth, both proteomic platforms provide relative protein abundances and not absolute plasma concentrations. Lastly, the relative contribution of various tissues to the plasma proteome is not knowable. In this study, we evaluated the possible association of a comprehensive set of coagulation-related proteins with VTE in COVID-19, showing that P-selectin is independently associated with development of VTE. This supports the mechanistic role of platelet/endothelial-activation in COVID-19-related thromboembolism. We found that measuring P-selectin levels at day 0 of hospitalization increases the diagnostic value of D-dimer alone, and that a combination of the two biomarkers (D-dimer and P-selectin) may provide a more accurate prediction of VTE in the setting of COVID-19. Further studies to address the utility of P-selectin as a predictive biomarker of VTE are warranted.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04435184CompletedCrizanlizumab for Treating COVID-19 Vasculopathy

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.07.10.21260293v1 on medRxiv